Health-related quality of life and inflammatory markers in malignant pleural mesothelioma
- 618 Downloads
Malignant pleural mesothelioma (MPM) is a highly aggressive and symptomatic disease. We examined the relationship between health-related quality of life (HRQoL) and inflammatory markers, and the prognostic role of HRQoL in MPM patients.
MPM patients from two parallel phase II studies (thalidomide alone or thalidomide with chemotherapy) were included. HRQoL was assessed at baseline using the modified Lung Cancer Symptom Scale (LCSS). Baseline inflammatory markers and cytokines were measured. Spearman correlation was used to examine the relationship between inflammatory markers and HRQoL measures. The prognostic value of the HRQoL domains was examined using Cox proportional hazard model.
Sixty-three patients were included: median age 61 years (range 44–79); 82 % male; 77 % Eastern Cooperative Oncology Group (ECOG) performance status 0–1; 44 % epithelial histology subtype. Baseline systemic symptoms of anorexia and fatigue, the summation symptoms of overall symptomatic distress, interference with normal activity and global QoL and the aggregate score of total LCSS score were all associated with elevated neutrophil-to-lymphocyte ratio, C-reactive protein and vascular endothelial growth factor levels at baseline (rho ≥ 0.25; p < 0.05). Baseline anorexia, fatigue, cough, dyspnoea, pain, overall symptomatic distress, interference with normal activity, global QoL and total LCSS score were all significantly related to survival (p < 0.05) after adjusting for established prognostic factors (age, gender, histological subtype and performance status) and treatment effect.
In conclusion, HRQoL seems to relate to a patient's systemic inflammatory status and is associated with survival in MPM patients.
KeywordsCancer Health-related quality of life Lung cancer symptom scale Malignant mesothelioma Sickness behaviour Systemic inflammation
This project was funded by the New South Wales Dust Diseases Compensation Board and the Estate of Mr. Clem Johnson, for financial support and Eli-Lilly for pharmaceutical support (supply of gemcitabine).
SCH Kao is supported by a National Health & Medical Research Council (NHMRC) postgraduate scholarship and a Research Scholar Award from the NSW Cancer Institute.
J Vardy is supported by the NSW Cancer Institute.
Conflict of interest statement
N Pavlakis is on an advisory board with E Lilly and has received a travel grant and speaking honoraria from E Lilly. N. van Zandwijk declares the following: advisory board for E Lilly, Merk Serono and Pfizer; speaker at Lilly Symposia.
- 1.Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644PubMedCrossRefGoogle Scholar
- 3.Nowak AK, Stockler MR, Byrne MJ (2004) Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the european organization for research and treatment of cancer core quality of life questionnaire and lung cancer module. J Clin Oncol 22:3172–3180PubMedCrossRefGoogle Scholar
- 5.Quinten C, Coens C, Mauer M, Comte S, Sprangers MAG, Cleeland C, Osoba D, Bjordal K, Bottomley A, Clinical Groups EORTC (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10:865–871PubMedCrossRefGoogle Scholar
- 6.Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, van Meerbeeck JP, EORTC-NCIC (2007) Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 25:5770–5776PubMedCrossRefGoogle Scholar
- 13.Kao SC, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, Yan TD, Vardy J, Clarke S, van Zandwijk N, McCaughan B (2011) Low calretinin expression and high Neutrophil-to-Lymphocyte Ratio are poor prognostic factors in malignant mesothelioma patients undergoing extrapleural pneumonectomy. J Thorac Oncol 6:1923–1929PubMedCrossRefGoogle Scholar
- 20.Kao SC, Harvie R, Paturi F, Taylor R, Davey R, Abraham R, Clarke S, Marx G, Cullen M, Kerestes Z, Pavlakis N (2012) The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer 75:248–254PubMedCrossRefGoogle Scholar
- 21.Hollen P, Gralla R, Kris M (1995) An overview of the Lung Cancer Symptom Scale. In: Gralla R, Moinpour C (eds) Assessing quality of life in patients with lung cancer: a guide for clinicians. NCM Publishers, New York, pp 57–59Google Scholar
- 23.van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RJ, van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G, European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881–6889PubMedCrossRefGoogle Scholar
- 26.Pusztai L, Mendoza T, Reuben J, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25:94–102PubMedCrossRefGoogle Scholar